Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals
Posted inInfectious Diseases news Public Health

Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals

In a phase 2a human challenge, high‑dose daily mosnodenvir substantially reduced DENV‑3 RNA burden versus placebo without serious adverse events, but treatment‑associated NS4B viral mutations emerged, highlighting efficacy and resistance concerns that require larger field studies.
Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term Safety
Posted inHematology-Oncology news Otorhinolaryngology

Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term Safety

In a randomized, double‑blind, placebo‑controlled proof‑of‑concept trial, oral engasertib reduced epistaxis frequency and duration in hereditary hemorrhagic telangiectasia (HHT) with a safety profile similar to placebo except for reversible rash and occasional hyperglycemia.
Ropeginterferon alfa-2b Superior to Anagrelide as Second-line Therapy in Hydroxyurea‑Intolerant or ‑Refractory Essential Thrombocythaemia: SURPASS‑ET Phase 3 Results
Posted inHematology-Oncology news

Ropeginterferon alfa-2b Superior to Anagrelide as Second-line Therapy in Hydroxyurea‑Intolerant or ‑Refractory Essential Thrombocythaemia: SURPASS‑ET Phase 3 Results

SURPASS‑ET, a phase 3 randomized trial, showed ropeginterferon alfa‑2b achieved durable ELN responses in 43% of hydroxyurea‑intolerant/refractory ET patients with leukocytosis versus 6% with anagrelide, with a favorable safety profile and fewer serious adverse events.
Combining Food Biodiversity, Less Processing, and the EAT‑Lancet Diet Improves Nutrient Adequacy and Lowers Environmental Impact: Insights from 368,733 EPIC Participants
Posted inFamily Medicine & Nutrition news Public Health

Combining Food Biodiversity, Less Processing, and the EAT‑Lancet Diet Improves Nutrient Adequacy and Lowers Environmental Impact: Insights from 368,733 EPIC Participants

Multi-objective optimization in the EPIC cohort shows that modest gains in adherence to the EAT‑Lancet diet, increased plant species richness, and substitution of ultra‑processed foods with minimally processed foods can raise nutrient adequacy and reduce greenhouse gas emissions and land use.
Rigid Gas-Permeable Contact Lenses Improve Visual Rehabilitation After Primary Congenital Glaucoma Surgery: Results of the CLEVR‑PCG Randomized Trial
Posted innews Ophthalmology Pediatrics

Rigid Gas-Permeable Contact Lenses Improve Visual Rehabilitation After Primary Congenital Glaucoma Surgery: Results of the CLEVR‑PCG Randomized Trial

In children after primary congenital glaucoma surgery with poor spectacle response, rigid gas‑permeable contact lenses produced greater improvements in worse‑eye visual acuity, contrast sensitivity, and near stereoacuity over 12 months compared with continued spectacle wear.
Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit
Posted inGastroenterology Infectious Diseases news

Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit

A 2025 bayesian meta-analysis of 14 RCTs (n=1,322) found shorter or no antibiotic prophylaxis after upper GI bleeding in cirrhosis was highly likely to be noninferior for mortality, though it increased reported bacterial infections. Study limitations temper definitive practice change.